Activist investing
Do Activists Have an Answer at Bed Bath & Beyond?
Is a turnaround even possible anymore?
Bed Bath & Beyond Continues Its Slide After Dismal Quarterly Report
Will BBBY be the next retailer to bite the dust?
Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
Charts of the Day: The States of U.S. Gambling
A bit of context to simmer on following the big deal between Caesars and Eldorado.
Where is the 'New' Caesars in the Casino Stock Standings?
Does a deal with Eldorado give Caesars all it needs to shift the market share dynamics in the casino industry?
Caesars Soars as Traders Hail Eldorado Resorts Deal
The $17 billion acquisition of Caesars by Eldorado is welcomed by activist investor Carl Icahn, who had been pushing Caesars board for a deal.
Chewy's Dual-Class Structure Isn't Ideal for Investors
Chewy is challenging strong criticism with its disparate dual-class structure.
Can Beyond Meat Beat the Significant Competition Bearing Down on It?
Competition may not be healthy for Beyond Meat's long-term bull case.
Allergan Stock Slips Despite Beat and Raised Guidance
Shares of the maker of Botox are struggling despite its latest results exceeding expectations.